To determine the effect of theophylline on respiratory muscle efficiency (RME), 12 normal subjects were given theophylline vs placebo in a double-blind, randomized crossover protocol. Spirometry, resting energy expenditure, minute ventilation, RME, and oxygen cost of breathing were measured at baseline, after taking theophylline, and after placebo. RME was calculated by dividing the added work required to breathe through a threshold load by the added energy consumed during loaded breathing. 
TPheophylline is the most widely prescribed bron--"-chodilator worldwide.1 In addition to its effect on airway muscle tone, theophylline is thought to owe some of its therapeutic efficacy to actions on the res¬ piratory muscles. Theophylline has been reported to have an inotropic effect on the diaphragm and to de¬ crease fatigability in both human2"5 and animal6,7 models. Although controversial,8 this effect has been demonstrated to improve respiratory muscle perfor¬ mance in patients with COPD5,9,10 and in patients with neuromuscular dysfunction.11 '12 Whether an improve¬ ment in contractility occurs at the expense ofincreased respiratory muscle tissue oxygen consumption or whether theophylline actually improves respiratory muscle efficiency is not known.
We evaluated the effect of theophylline on mea¬ surements of respiratory muscle efficiency (RME) and oxygen cost of breathing in a group of normal subjects. RME increased significantly when subjects were given theophylline (Fig 1, Table 2 ). There was a significant difference among baseline, placebo, and theophylline treatment arms (xr2=9.75, p<0.005). There was no significant difference between baseline and placebo treatments; however, there were signifi¬ cant differences between baseline and theophylline (mean difference, 4.6%; p<0.01), and between placebo and theophylline treatments (mean difference, 3 Oxygen cost of breathing decreased when subjects were given theophylline (Fig 2, Table 2 ). There was a significant difference among the three treatment arms (Xr2=6. 25 
